LEWISBERRY, Pa., Sept. 1 /PRNewswire-FirstCall/ -- Unilife Corporation (“Unilife” or “Company”) (Nasdaq: UNIS, ASX: UNS), today announced that its Unitract Tuberculin (TB) Syringe has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA).
The Unitract TB syringe is a variant of the Unitract 1mL Insulin Syringe for which Unilife secured FDA clearance earlier this year. Unlike insulin syringes which are primarily used by people with diabetes, TB syringes are used for the administration of a range of therapeutic drugs and vaccines within acute-care hospitals and other healthcare facilities.
The Unitract range of 1mL syringes is the world’s first and only known syringe that allows operators to control the speed of passive (automatic) needle retraction directly from the patient’s body into the barrel of the syringe where it is locked in place. The products are well positioned to help prevent the transmission of blood-borne diseases such as HIV and hepatitis C via needlestick injuries, aerosol dispersal and syringe reuse. Primary target markets of the products include healthcare facilities, pharmaceutical companies and patients who self-administer prescription medication. Production of the Unitract 1mL syringe is occurring at Unilife’s FDA-registered manufacturing facility in Lewisberry, Pennsylvania.
Mr. Alan Shortall, Chief Executive Officer of Unilife, stated, “U.S. FDA 510k market clearance for our Unitract TB syringe marks an important step in our company’s efforts to bring a complete line of safety syringes to market, as it is our second product to receive this clearance. With TB syringes most commonly used within acute-care hospitals and other healthcare facilities, FDA clearance of our Unitract TB syringe significantly broadens our capacity to market our unique products across the U.S. and other key international markets.”
Unilife has also recently secured its EC certification to apply the CE Mark to its Unitract 1mL syringes manufactured at its Lewisberry facility, allowing the sale and distribution of these products within the European Union and Australia.
The Company also expects to complete studies required to attain a five-year shelf life expiration date for its full range of Unitract 1mL syringes in September. The inclusion of a five-year expiry date on medical device packaging is considered to be the gold-standard within the industry, and should help to finalize discussions with a number of interested U.S. healthcare distributors in the near future.
About Unilife Corporation
Unilife Corporation is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485 certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in “Item 1A. Risk Factors” and elsewhere in our registration statement on Form 10 and those described from time to time in our periodic reports which we file with the Securities and Exchange Commission.
General: UNIS-G
Investor Contacts (US): | Investor Contacts (Australia) | ||
Todd Fromer / Garth Russell | Stuart Fine | Jeff Carter | |
KCSA Strategic Communications | Carpe DM Inc | Unilife Corporation | |
Phone + 1 212-682-6300 | Phone + 1 908 469 1788 | Phone + 61 2 8346 6500 | |
SOURCE Unilife Corporation
